Prostate cancer drug screening using hKLK2 enhancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 18, 2000
Issued Date -
N/A
app pub date -
Aug 4, 1997
filing date -
Aug 6, 1996
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Screening of compounds for activity toward inhibition of prostate cancer cell proliferation is provided. A cell line containing an expression construct comprising a transciptional initiation region of a prostate specific enhancer from a human glandular kallikrein (hKLK2) gene is employed which can be used in conventional equipment for determining activity of compounds, where the cell line uses a marker whose expression is responsive to therapeutically active compounds.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully